UNSPSC 51142529: Lazabemide

This classification denotes a monoamine oxidase inhibitor with the molecular formula C8H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 420HD787N9, chemically known as 2-pyridinecarboxamide, n-(2-aminoethyl)-5-chloro- but generally known as lazabemide, which bears US NIH Compound Identifier 71307. European Medicines Agency schedules Lazabemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08418MIG. The term LAZABEMIDE is an International Non-Proprietary Name.

UNSPSC 51142529 Lazabemide is a Commodity-level code representing pharmaceutical products that state and local government agencies procure for community health, emergency response, and pharmacy benefit programs. Recent solicitations show that state and local bodies are acquiring naloxone and drug deactivation systems for public health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models to improve supply chain efficiency and cost management. The issuing-body mix includes county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that coordinate procurement across participating jurisdictions. The work spans both commodity purchasing of standardized pharmaceutical products and exploratory procurement activities designed to reshape how states contract for prescription medications outside traditional pharmacy benefit manager intermediaries.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring alternatives to traditional pharmacy benefit manager and group purchasing organization models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors responding to MMCAP must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and accept a 3 percent administrative fee structure with performance penalties for non-compliance.